On Nov 09, major Wall Street analysts update their ratings for $Evolent Health (EVH.US)$, with price targets ranging from $27 to $63.
Barclays analyst Stephanie Davis maintains with a buy rating, and maintains the target price at $39.
TD Cowen analyst Charles Rhyee maintains with a buy rating, and maintains the target price at $63.
Oppenheimer analyst Michael Wiederhorn maintains with a buy rating, and adjusts the target price from $45 to $34.
BTIG analyst David Larsen maintains with a buy rating, and adjusts the target price from $45 to $36.
JMP Securities analyst Constantine Davides maintains with a buy rating, and adjusts the target price from $43 to $27.
Furthermore, according to the comprehensive report, the opinions of $Evolent Health (EVH.US)$'s main analysts recently are as follows:
Evolent Health's Q3 EBITDA was notably lower than the consensus, primarily due to a marked rise in Oncology costs, both retrospective and within the quarter. On a positive note, the company secured $200M in new run-rate business during Q3, underscoring the increased demand for specialty care management.
Evolent Health's Q3 outcomes were described as below expectations. Previously, it appeared that the company was on course to offset rising costs through contractual rate increases. Despite this, the recent stock selloff implies skepticism among investors about the company's ability to achieve approximately $300M in EBITDA. Nonetheless, the belief is that the recent circumstances are atypical and that Evolent's margins will return to normal as the rate increases are implemented.
Here are the latest investment ratings and price targets for $Evolent Health (EVH.US)$ from 5 analysts:
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
美東時間11月9日，多家華爾街大行更新了$Evolent Health (EVH.US)$的評級，目標價介於27美元至63美元。
巴克萊銀行分析師Stephanie Davis維持買入評級，維持目標價39美元。
TD Cowen分析師Charles Rhyee維持買入評級，維持目標價63美元。
奧本海默控股分析師Michael Wiederhorn維持買入評級，並將目標價從45美元下調至34美元。
BTIG分析師David Larsen維持買入評級，並將目標價從45美元下調至36美元。
JMP Securities分析師Constantine Davides維持買入評級，並將目標價從43美元下調至27美元。
此外，綜合報道，$Evolent Health (EVH.US)$近期主要分析師觀點如下：
evolent health的Q3 EBITDA明顯低於共識，主要是由於腫瘤學成本顯著上升，不論是回顧性的還是季度內的。值得一提的是，該公司在Q3期間獲得了新的$20000萬經營業務，突顯出特殊護理管理領域需求增加。
evolent health的Q3業績被描述爲低於預期。此前，公司曾似乎打算通過合同費率提高來抵消不斷上升的成本。儘管如此，最近的股票拋售暗示投資者對公司能否實現約$30000萬的EBITDA存在懷疑。然而，人們相信最近的情況是非典型的，並且隨着費率的增加實施，evolent health的利潤率將恢復正常。
以下爲今日5位分析師對$Evolent Health (EVH.US)$的最新投資評級及目標價：
提示:
TipRanks為獨立第三方，提供金融分析師的分析數據，並計算分析師推薦的平均回報率和勝率。提供的信息並非投資建議，僅供参考。本文不對評級數據和報告的完整性與準確性做出認可、聲明或保證。
TipRanks提供每位分析師的星級，分析師星級代表分析師所有推薦的過往表現，通過分析師的總勝率和平均回報率综合計算得出，星星越多，則該分析師過往表現越優異，最高爲5颗星。
分析師總勝率為近一年分析師的評級成功次數占總評級次數的比率。評级的成功與否，取決於TipRanks的虚擬投資組合是否從該股票中產生正回報。
總平均回報率為基於分析師的初始評級創建虚擬投資組合，並根據評級變化對組合進行調整，在近一年中該投資組合所獲得的回報率。
